Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07343024Recruiting

Methods of Identifying Effective Off-Guideline Treatments for Advanced Cancer Patients (CC N-of-1)

Role: lead

NCT04566393Unknown

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Role: collaborator

NCT03793088Unknown

A Patient-Centric Platform Trial for Precision Oncology

Role: collaborator

NCT04321811Completed

Behavior, Environment And Treatments for Covid-19

Role: collaborator

All 4 trials loaded